<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871687</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000094</org_study_id>
    <nct_id>NCT02871687</nct_id>
  </id_info>
  <brief_title>Effect of Statin Use on Aldosterone Secretion</brief_title>
  <official_title>Effect of Statin Use on Aldosterone Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research protocol is to determine if the same effects are observed in&#xD;
      vivo in humans through a randomized controlled study. Data regarding a novel mechanism of the&#xD;
      widely used statin class of medications on the mineralocorticoid pathway would likely have&#xD;
      significant clinical implications on the future management of hypertension and other&#xD;
      cardiovascular disease given the known pleiotropy of aldosterone action.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to provide additional evidence regarding the effect of statin therapy on aldosterone&#xD;
      levels, the investigators propose the following randomized, double-blinded, placebo&#xD;
      controlled protocol in relatively healthy volunteers. The investigators will evaluate&#xD;
      aldosterone and cortisol production in response to an angiotensin II infusion under the&#xD;
      following test conditions: 1) placebo, 2) simvastatin therapy (lipophilic statin), and 3)&#xD;
      pravastatin therapy (hydrophilic statin). Measurements will be made to assess the effect of&#xD;
      both acute (single dose) and chronic (6 and 12 weeks) therapy of the two statin medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum aldosterone following angiotensin II infusion</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 20 mg daily followed by potential increase to 40 mg simvastatin according to dose escalation procedure</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pravastatin 40 mg daily followed by potential increase to 80 mg pravastatin according to dose escalation procedure</description>
    <arm_group_label>Pravastatin</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood pressure &lt;140/90 mmHg and &gt;90/50 mmHg&#xD;
&#xD;
          -  Body mass index 19-40 kg/m2&#xD;
&#xD;
          -  Normal screening laboratory values for:&#xD;
&#xD;
             i. Serum sodium, potassium, glucose, liver enzymes ii. GFR (&gt;60 mL/min/1.73m2) iii.&#xD;
             A1c iv. TSH&#xD;
&#xD;
          -  Normal ECG&#xD;
&#xD;
          -  Negative urine HCG at screening for women who are able to become pregnant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior use of statin therapy&#xD;
&#xD;
          -  History of coronary disease, diabetes, hypertension, stroke, kidney disease, thyroid&#xD;
             disease, psychiatric illness, malignancy, preeclampsia, or illness requiring overnight&#xD;
             hospitalization in the past 6 months&#xD;
&#xD;
          -  Triglycerides &gt; 500, LDL &gt; 200&#xD;
&#xD;
          -  Any prescription medication or herbal medication including oral contraceptive,&#xD;
             excluding thyroid medications&#xD;
&#xD;
          -  Unstable thyroid disease (determined by abnormal TSH)&#xD;
&#xD;
          -  Pregnancy or current breastfeeding&#xD;
&#xD;
          -  Alcohol intake &gt;12 oz per week&#xD;
&#xD;
          -  Tobacco or recreational drug use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital- 221 Longwood Avenue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baudrand R, Pojoga LH, Vaidya A, Garza AE, VÃ¶hringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.</citation>
    <PMID>26432671</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jonathan S. Williams, MD, MMSc</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

